This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Robert A. O'Reilly, MD
Stanford, Calif

Patrick Kearns, MD
San Jose, Calif

Arch Intern Med. 1995;155(19):2127.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The article on antithrombotic therapy¹ that appeared in the January 23, 1995, issue of the ARCHIVES was introduced as a synopsis of the proposed guidelines for an American College of Chest Physicians Consensus Conference on Antithrombotic Therapy, including recent updates and information that will likely influence future recommendations. The authors recommend reversing the anticoagulant effects of warfarin when the international normalized ratio is between 6.0 and 10.0 and "the patient is not bleeding," with vitamin K given by slow intravenous injection in a dose of 0.5 to 1.0 mg, and when the international normalized ratio is between 10.0 and 20.0 and "the patient is not bleeding," with a higher dose of vitamin K (3 to 5 mg), also by slow intravenous injection. Their statement that "intravenous vitamin K therapy has been associated with a slightly increased risk of anaphylaxis" is specious at best and deadly at worst. Well over . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?